Johanna Bendell
Hematology & Oncology · Nashville, TNNPI 1083703540
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Roche TCRC, Inc. at 53.9% of the total. Reporting peaked in 2021 at $40,852 and has fallen 99.9% since, to $23 in 2022.
Across 48 payments — averaging $1199.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Roche TCRC, Inc.$31K
- F. Hoffmann-la Roche AG$9K
- Daiichi Sankyo Inc.$5K
- Boehringer Ingelheim International GmbH$3K
- AbbVie$3K
- Incyte Corporation$3K
- plus $5K from 11 others
Across 2,861 payments — averaging $9938.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$5.5M
- Merck$4.9M
- E.r. Squibb & Sons, L.L.C.$3.5M
- Eli Lilly$2.1M
- Amgen$1.4M
- Genentech, Inc.$1.4M
- plus $9.5M from 37 others
What the payments were for
- Consulting fees$34,21359%
- Speaking & faculty fees$20,66636%
- Travel & lodging$1,8463%
- Food & beverage$8712%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Roche TCRC, Inc. | 1 | $31,020 |
| F. Hoffmann-la Roche AG | 5 | $8,869 |
| Daiichi Sankyo Inc. | 1 | $4,500 |
| Boehringer Ingelheim International GmbH | 5 | $3,147 |
| AbbVie | 1 | $2,693 |
| Incyte Corporation | 1 | $2,639 |
| Pfizer | 6 | $2,081 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 4 | $1,511 |
| Samsung Bioepis Co., Ltd. | 1 | $500 |
| Merck | 7 | $223 |
| Genentech USA, Inc. | 1 | $109 |
| Daiichi Sankyo Company LTD | 1 | $83 |
| Novartis | 5 | $83 |
| Astellas Pharma US Inc | 5 | $65 |
| GSK | 2 | $35 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $23 |
| Eisai Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$57,595 in reported general payments places this provider in the 80th percentile of 251 hematology & oncology providers in Tennessee.
Other hematology & oncology in Nashville
- Jonathan AbbasNashville$1.3M
- Alan TanNashville$1.1M
- Kent ShihNashville$900K
- Brian RiniNashville$601K
- Wade IamsNashville$601K
- Krish PatelNashville$531K
- Sandeep RajanNashville$465K
- Todd BauerNashville$357K
- Muhamed BaljevicNashville$313K
- Olalekan OluwoleNashville$311K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.